Financial Contrast: Ocera Therapeutics (TZYM) vs. Onconova Therapeutics (ONTX)
Ocera Therapeutics (NASDAQ: TZYM) and Onconova Therapeutics (NASDAQ:ONTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitabiliy.
Insider & Institutional Ownership
15.5% of Onconova Therapeutics shares are owned by institutional investors. 27.3% of Onconova Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of recent ratings for Ocera Therapeutics and Onconova Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Onconova Therapeutics has a consensus target price of $8.00, indicating a potential upside of 294.09%. Given Onconova Therapeutics’ higher possible upside, analysts clearly believe Onconova Therapeutics is more favorable than Ocera Therapeutics.
Valuation & Earnings
This table compares Ocera Therapeutics and Onconova Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Onconova Therapeutics||$4.28 million||4.50||-$19.88 million||($4.02)||-0.50|
Ocera Therapeutics has higher revenue, but lower earnings than Onconova Therapeutics.
This table compares Ocera Therapeutics and Onconova Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Onconova Therapeutics beats Ocera Therapeutics on 6 of the 8 factors compared between the two stocks.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Receive News & Ratings for Ocera Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.